BB Biotech
Latest statistics and disclosures from Bb Biotech's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IONS, INCY, NBIX, VRTX, SAGE, and represent 42.56% of Bb Biotech's stock portfolio.
- Added to shares of these 10 stocks: CRSP (+$29M), Audentes Therapeutics (+$23M), NKTR (+$22M), Myokardia (+$20M), Intercept Pharmaceuticals In (+$14M), SGMO (+$12M), Kezar Life Sciences (+$7.1M), AGIO (+$6.7M), ALNY (+$5.6M), ESPR (+$5.2M).
- Started 2 new stock positions in CRSP, Homology Medicines.
- Reduced shares in these 7 stocks: IONS (-$83M), , INCY (-$16M), VRTX (-$13M), GILD (-$12M), Celgene Corporation (-$9.8M), Akcea Therapeutics Inc equities.
- Sold out of its position in REGN.
- Bb Biotech was a net seller of stock by $-513k.
- Bb Biotech has $4.0B in assets under management (AUM), dropping by 27.44%.
- Central Index Key (CIK): 0000924223
Tip: Access up to 7 years of quarterly data
Positions held by BB Biotech consolidated in one spreadsheet with up to 7 years of data
Download as csv

Portfolio Holdings for Bb Biotech
Bb Biotech holds 35 positions in its portfolio as reported in the March 2019 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|
---|---|---|---|---|---|---|
Ionis Pharmaceuticals (IONS) | 15.8 | $627M | -11% | 7.7M | 81.17 |
|
Incyte Corporation (INCY) | 7.8 | $311M | -4% | 3.6M | 86.01 |
|
Neurocrine Biosciences (NBIX) | 7.5 | $297M | 3.4M | 88.10 |
|
|
Vertex Pharmaceuticals Incorporated (VRTX) | 6.0 | $239M | -5% | 1.3M | 183.95 |
|
Sage Therapeutics (SAGE) | 5.5 | $219M | 1.4M | 159.05 |
|
|
Celgene Corporation | 5.2 | $208M | -4% | 2.2M | 94.34 |
|
Agios Pharmaceuticals (AGIO) | 5.0 | $201M | +3% | 3.0M | 67.44 |
|
Alexion Pharmaceuticals | 4.5 | $178M | 1.3M | 135.18 |
|
|
Alnylam Pharmaceuticals (ALNY) | 3.8 | $152M | +3% | 1.6M | 93.45 |
|
Esperion Therapeutics (ESPR) | 3.6 | $141M | +3% | 3.5M | 40.15 |
|
Radius Health | 3.4 | $135M | 6.8M | 19.94 |
|
|
Halozyme Therapeutics (HALO) | 3.4 | $134M | 8.3M | 16.10 |
|
|
Argenx Se (ARGX) | 2.8 | $113M | +2% | 905k | 124.84 |
|
Moderna (MRNA) | 2.5 | $97M | 4.8M | 20.35 |
|
|
Myovant Sciences | 2.2 | $86M | 3.6M | 23.87 |
|
|
Intercept Pharmaceuticals In | 2.0 | $78M | +21% | 697k | 111.86 |
|
Gilead Sciences (GILD) | 1.9 | $74M | -14% | 1.1M | 65.01 |
|
Nektar Therapeutics (NKTR) | 1.7 | $68M | +46% | 2.0M | 33.60 |
|
Exelixis (EXEL) | 1.7 | $68M | 2.8M | 23.80 |
|
|
Akcea Therapeutics Inc equities | 1.7 | $67M | 2.4M | 28.33 |
|
|
Myokardia | 1.6 | $66M | +44% | 1.3M | 51.99 |
|
Macrogenics (MGNX) | 1.5 | $61M | +3% | 3.4M | 17.98 |
|
Wave Life Sciences (WVE) | 1.4 | $57M | 1.5M | 38.85 |
|
|
Voyager Therapeutics (VYGR) | 1.4 | $55M | 2.9M | 19.14 |
|
|
Audentes Therapeutics | 1.3 | $53M | +78% | 1.4M | 39.02 |
|
Alder Biopharmaceuticals | 0.9 | $38M | 2.8M | 13.65 |
|
|
Crispr Therapeutics (CRSP) | 0.7 | $29M | NEW | 811k | 35.72 |
|
Scholar Rock Hldg Corp (SRRK) | 0.7 | $28M | +15% | 1.5M | 18.79 |
|
Intra Cellular Therapies (ITCI) | 0.7 | $27M | 2.2M | 12.18 |
|
|
Sangamo Biosciences (SGMO) | 0.6 | $25M | +96% | 2.7M | 9.54 |
|
Kezar Life Sciences | 0.5 | $22M | +49% | 1.2M | 17.74 |
|
G1 Therapeutics | 0.3 | $11M | 672k | 16.60 |
|
|
Cidara Therapeutics Inc Common Stock Usd 0.0001 | 0.1 | $6.1M | 2.3M | 2.65 |
|
|
Novavax | 0.1 | $4.6M | 8.3M | 0.55 |
|
|
Homology Medicines | 0.1 | $2.5M | NEW | 91k | 27.73 |
|
Past Filings by Bb Biotech
SEC 13F filings are viewable for Bb Biotech going back to 2010
- Bb Biotech 2019 Q1 filed May 13, 2019
- Bb Biotech 2018 Q4 filed Feb. 12, 2019
- Bb Biotech 2018 Q3 filed Nov. 9, 2018
- Bb Biotech 2018 Q2 filed Aug. 9, 2018
- Bb Biotech 2018 Q1 filed May 8, 2018
- Bb Biotech 2017 Q4 filed Feb. 14, 2018
- Bb Biotech 2017 Q3 filed Nov. 13, 2017
- Bb Biotech 2017 Q2 filed Aug. 11, 2017
- Bb Biotech 2017 Q1 filed May 10, 2017
- Bb Biotech 2016 Q4 filed Feb. 14, 2017
- Bb Biotech 2016 Q3 filed Nov. 10, 2016
- Bb Biotech 2016 Q2 filed Aug. 12, 2016
- Bb Biotech 2016 Q1 filed May 12, 2016
- Bb Biotech 2015 Q4 filed Feb. 9, 2016
- Bb Biotech 2015 Q3 filed Nov. 12, 2015
- Bb Biotech 2015 Q2 filed Aug. 12, 2015